2022 - Research.com Immunology in Spain Leader Award
Bonaventura Clotet mostly deals with Virology, Immunology, Viral load, Internal medicine and Virus. Bonaventura Clotet has researched Virology in several fields, including Peripheral blood mononuclear cell and Drug resistance. As a part of the same scientific study, Bonaventura Clotet usually deals with the Immunology, concentrating on Acquired immunodeficiency syndrome and frequently concerns with Transmission, Family medicine and Hepatitis C virus.
His study in Viral load is interdisciplinary in nature, drawing from both Clinical trial, Regimen, Tolerability, Human leukocyte antigen and Enfuvirtide. His work deals with themes such as Gastroenterology, Placebo, Surgery and Ritonavir, which intersect with Internal medicine. In his study, Integrase inhibitor is strongly linked to Pharmacology, which falls under the umbrella field of Ritonavir.
Bonaventura Clotet mainly focuses on Virology, Internal medicine, Immunology, Viral load and Virus. His Virology research integrates issues from Reverse transcriptase, Drug resistance and Genotype. Bonaventura Clotet interconnects Gastroenterology, Oncology and Ritonavir in the investigation of issues within Internal medicine.
His research in Ritonavir intersects with topics in Protease inhibitor, Darunavir, Lopinavir and Pharmacology. His work on Acquired immunodeficiency syndrome expands to the thematically related Immunology. His Viral load research incorporates themes from Surgery, Adverse effect, Placebo, Pharmacotherapy and Lamivudine.
His main research concerns Internal medicine, Immunology, Immune system, Virology and Viral load. Internal medicine is closely attributed to Oncology in his work. The study incorporates disciplines such as Phenotype and Prospective cohort study in addition to Immunology.
Bonaventura Clotet has included themes like Epitope, Cytotoxic T cell and Monoclonal antibody in his Immune system study. His research integrates issues of Inoculation, Antibody and Severe acute respiratory syndrome coronavirus 2 in his study of Virology. His studies in Viral load integrate themes in fields like Pharmacotherapy and Viral replication.
The scientist’s investigation covers issues in Internal medicine, Immunology, Immune system, Viral load and Oncology. Many of his studies involve connections with topics such as Prospective cohort study and Immunology. His Immune system study combines topics from a wide range of disciplines, such as Vaccination, Virology and Antibody, Neutralization, Monoclonal antibody.
He combines subjects such as Antibody-dependent cell-mediated cytotoxicity and Antigen with his study of Virology. His Viral load study incorporates themes from Discontinuation, Dolutegravir, Maintenance therapy, Integrase inhibitor and Pharmacotherapy. His Randomized controlled trial research is multidisciplinary, incorporating elements of Lamivudine and Incidence.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-1: 24-week results from a randomised, double-blind, placebo-controlled trial.
Adriano Lazzarin;Thomas Campbell;Bonaventura Clotet;Margaret Johnson.
The Lancet (2007)
Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: a pooled subgroup analysis of data from two randomised trials
Bonaventura Clotet;Nicholas Bellos;Jean Michel Molina;David Cooper.
The Lancet (2007)
Once-daily dolutegravir versus darunavir plus ritonavir in antiretroviral-naive adults with HIV-1 infection (FLAMINGO): 48 week results from the randomised open-label phase 3b study
Bonaventura Clotet;Judith Feinberg;Jan Van Lunzen;Marie Aude Khuong-Josses.
The Lancet (2014)
Durable efficacy of tipranavir-ritonavir in combination with an optimised background regimen of antiretroviral drugs for treatment-experienced HIV-1-infected patients at 48 weeks in the Randomized Evaluation of Strategic Intervention in multi-drug reSistant patients with Tipranavir (RESIST) studies: an analysis of combined data from two randomised open-label trials
Charles B Hicks;Pedro Cahn;David A Cooper;Sharon L Walmsley.
The Lancet (2006)
Antiretroviral Drug Resistance Testing in Adult HIV-1 Infection
Martin S. Hirsch;Scott M. Hammer;Victoria A. Johnson;Daniel R. Kuritzkes.
Suppression of chemokine receptor expression by RNA interference allows for inhibition of HIV-1 replication.
Miguel A Martínez;Arantxa Gutiérrez;Mercedes Armand-Ugón;Julià Blanco.
Safety and Efficacy of Dolutegravir in Treatment-Experienced Subjects With Raltegravir-Resistant HIV Type 1 Infection: 24-Week Results of the VIKING Study
Joseph J. Eron;Bonaventura Clotet;Jacques Durant;Christine Katlama.
The Journal of Infectious Diseases (2013)
A randomized trial to study first-line combination therapy with or without a protease inhibitor in HIV-1-infected patients.
Remko Van Leeuwen;Christine Katlama;Robert Murphy;Kathleen Squires.
Long-term efficacy and safety of Raltegravir combined with optimized background therapy in treatment-experienced patients with drug-resistant HIV infection: week 96 results of the BENCHMRK 1 and 2 Phase III trials
Roy T. Steigbigel;David A. Cooper;Hedy Teppler;Joseph J. Eron.
Clinical Infectious Diseases (2010)
Update of the drug resistance mutations in HIV-1: Fall 2006.
Victoria A Johnson;Francoise Brun-Vezinet;Bonaventura Clotet;Daniel R Kuritzkes.
Topics in HIV medicine : a publication of the International AIDS Society, USA (2006)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: